Weight-Based Anti-C5 Dosing for Pediatric PNH Hemolysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pediatric patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) face substantial morbidity due to hemolysis and other symptoms, with limited clinical studies and effective treatments, necessitating improved therapeutic methods.
Innovation Solution
Administering anti-C5 antibodies, such as ravulizumab or its antigen binding fragments, following specific clinical dosage regimens tailored to pediatric patients' weights, including initial doses and subsequent administration schedules to maintain effective serum trough concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-C5 antibodies are administered to pediatric PNH patients, then hemolysis is reduced and symptoms are alleviated, but dosage optimization is challenging due to limited clinical studies
Solution Approach 1:
The patent applies parameter changes by establishing weight-based dosage regimens that adjust the amount of anti-C5 antibody administered according to pediatric patient weight categories. This transforms the fixed dosage approach into a variable parameter system that accounts for patient size differences, thereby optimizing treatment efficacy while simplifying the clinical decision-making process.
Solution Approach 2:
The patent segments the pediatric patient population into distinct weight-based categories (e.g., <20 kg, 20-40 kg, >40 kg) and assigns specific dosage schedules to each segment. This segmentation allows for precise dosage optimization without requiring complex individualized calculations, resolving the contradiction between treatment reliability and regimen complexity.
2Manufacturing precision
If weight-based dosage regimens are implemented, then treatment efficacy is optimized, but administration complexity increases
Solution Approach 1:
The patent performs preliminary action by pre-calculating and establishing fixed dosage regimens for each weight category before clinical administration. This allows clinicians to simply select the appropriate pre-determined regimen based on patient weight, achieving precise dosage optimization without requiring complex real-time calculations or adjustments during administration.
3Reliability
If serum trough concentrations are maintained within specific ranges, then hemolysis control is improved, but monitoring and adjustment requirements increase
Solution Approach 1:
The patent applies self-service by designing dosage regimens that automatically maintain serum trough concentrations within the therapeutic range through pre-calculated dosing intervals and amounts. The regimen itself provides the necessary adjustments to maintain effective concentrations without requiring continuous external monitoring or intervention, thereby improving hemolysis control while preserving clinical workflow efficiency.
Data Source
AI summary
Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in pediatric patients using an anti-C5 antibody, or antigen binding fragment thereof.